Major Depressive Disorder Clinical Trial
Official title:
A Pilot Study to Evaluate Individualized Choice of Antidepressant in Patients With Cancer
This is a pilot study to test the hypothesis that the antidepressants mirtazapine and citalopram are effective treatment for major depressive disorder (MDD) in cancer patients.
Major depressive disorder (MDD) is a debilitating illness associated with increased
mortality and significant impairment in quality of life. The prevalence of MDD is
particularly high in patients with cancer, as much as 38% in some studies.
The study of depression in cancer patients is particularly important, as these co-morbid
illnesses can frequently complicate the management of each other. In addition to affecting
quality of life, poorly controlled depression can affect cancer treatment adherence and can
lead to poor treatment outcomes.
Depression can be challenging to diagnose in patients with cancer. A spectrum of depressive
symptoms can be seen, ranging from appropriate sadness in response to a life threatening
diagnosis, to a major depressive episode. The diagnosis is confounded by the symptoms
brought on by the cancer and its treatment, such as fatigue, insomnia, anorexia, and pain.
Medications commonly used in cancer patients such as narcotics, benzodiazepines,
antihistamines, steroids, antibiotics, chemotherapy, and endocrine therapy can all lead to
side effects that further confuse the picture. However, while challenging, evidence does
suggest that a valid diagnosis of depression can be made in this patient population.
The current standard for diagnosing MDD is the Diagnostic and Statistical Manual of Mental
Disorders - Fourth Edition - Text Revision (DSM-IV-TR), which was published in 2000 by the
American Psychiatric Association. The diagnosis is made based on an interview between the
patient and physician in which nine criteria are assessed, including depressed mood,
anhedonia, weight loss or gain, insomnia or hypersomnia, psychomotor agitation or
retardation, fatigue, feelings of worthlessness or guilt, difficulty concentrating, and
recurrent thoughts of death. In patients with cancer, the diagnosis of MDD is more often
based on anhedonia and feelings of worthlessness, as depressed mood, weight fluctuation, and
sleep disturbance can be symptoms of the underlying cancer itself. Once the diagnosis has
been made, there are several tools which have been created and validated for the purpose of
assessing the severity of depression and for following the severity over time. The tool we
intend to use in this study is the PHQ-9.
Therapy for MDD in the general population includes both psychotherapy and pharmacological
intervention. However, the optimal therapy of MDD in cancer patients remains uncertain. Very
few placebo controlled trials have been performed in this population, and there is currently
no uniformly accepted standard of care. Some of the evidence from studies in depressed but
otherwise medically healthy patients may be applicable to cancer patients, but there are
several factors which complicate the treatment of depression in this group. For example, the
overlap of symptoms between depression and the underlying malignancy can confound the
diagnosis, as discussed earlier. Simultaneous treatment of the underlying malignancy
introduces adverse effects from surgery, chemotherapy, or radiation, as well as an increased
likelihood of drug-drug interactions. Finally, co-morbid conditions such as cancer pain can
contribute to the depression, requiring simultaneous therapy. As a result of these unique
factors, the treatment of MDD in cancer patients cannot necessarily be approached using the
standard recommendations for the general population.
There is scant evidence supporting the effectiveness of pharmacologic therapy in cancer
patients with MDD. In the last 25 years only four placebo controlled trials have been
published, and of these only two have shown a statistically significant improvement in
depression scores with active treatment.
Additional studies are needed to evaluate some of the newer antidepressants within the
cancer population and to assess whether this strategy of matching side effects to symptoms
is beneficial.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |